New antibody PRL3-Zumab tested against advanced cancers
NCT ID NCT07290088
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called PRL3-zumab in 52 adults with advanced solid tumors. The drug is given by IV every two weeks. Researchers want to see if it can slow cancer growth and how safe it is. Participants must have had no more than three prior treatments and be in relatively good health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRL3-zumab (an experimental antibody given by IV infusion every 2 weeks)
What this could lead to
If successful, this could provide a new treatment option to slow tumor growth in patients with advanced solid cancers.
What could go wrong
This is an early-to-mid-stage trial with only 52 participants, so results may not apply broadly. The drug may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beacon Hospital
RECRUITINGKuala Lumpur, Malaysia
Contact Email: •••••@•••••
-
Hosp. Kuala Lumpur
RECRUITINGKuala Lumpur, Malaysia
Contact Email: •••••@•••••
-
Hosp. Universiti Sains Malaysia (HUSM), Kelantan
RECRUITINGKota Bharu, Malaysia
Contact Email: •••••@•••••
-
University Malaysia Medical Centre
RECRUITINGKuala Lumpur, Malaysia
Contact Email: •••••@•••••
Contact